Generics in Japan

Date: January 4, 2016
Pages: 33
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GDBE6BEE215EN
Leaflet:

Download PDF Leaflet

INTRODUCTION

Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Japan generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Japanese generics market is expected to generate total revenues of $10.2bn in 2015, representing a compound annual growth rate (CAGR) of 2.5% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 43.4 % of total pharma volume in 2015.
  • Unlike its G8 peers, generic market share in Japan is rather low. Due to an aging population and rising costs of branded drugs, healthcare policies to cut expenditure on medical costs have been implemented. These policies aim to increase generic market share to 80% of volume between 2018 and 2020.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Japan
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the Japan economy
KEY QUESTIONS ANSWERED
  • What was the size of the Japan generics market by value in 2015?
  • What will be the size of the Japan generics market in 2020?
  • What factors are affecting the strength of competition in the Japan generics market?
  • How has the market performed over the last five years?
  • How large is Japan’s generics market in relation to its regional counterparts?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Daiichi Sankyo Co., Ltd.
Sawai Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country Data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Japan generics market value: $ billion, 2011–15(e)
Table 2: Japan generics market volume: % of total pharma volume, 2011–15(e)
Table 3: Japan generics market geography segmentation: $ billion, 2015(e)
Table 4: Japan generics market value forecast: $ billion, 2015–20
Table 5: Japan generics market volume forecast: % of total pharma volume, 2015–20
Table 6: Daiichi Sankyo Co., Ltd.: key facts
Table 7: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 8: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 9: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 10: Sawai Pharmaceutical Co., Ltd.: key facts
Table 11: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 12: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
Table 13: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: Japan size of population (million), 2011–15
Table 18: Japan gdp (constant 2005 prices, $ billion), 2011–15
Table 19: Japan gdp (current prices, $ billion), 2011–15
Table 20: Japan inflation, 2011–15
Table 21: Japan consumer price index (absolute), 2011–15
Table 22: Japan exchange rate, 2011–15

LIST OF FIGURES

Figure 1: Japan generics market value: $ billion, 2011–15(e)
Figure 2: Japan generics market volume: % of total pharma volume, 2011–15(e)
Figure 3: Japan generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Japan generics market value forecast: $ billion, 2015–20
Figure 5: Japan generics market volume forecast: % of total pharma volume, 2015–20
Figure 6: Forces driving competition in the generics market in Japan, 2015
Figure 7: Drivers of buyer power in the generics market in Japan, 2015
Figure 8: Drivers of supplier power in the generics market in Japan, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2015
Figure 12: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 13: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 14: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 15: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Skip to top


Japanese Generic Market Forecast to 2013 US$ 800.00 Mar, 2011 · 45 pages
Zydus Cadila Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 12 pages
Japan Pharmaceuticals and Healthcare Report Q4 2015 US$ 1,295.00 Aug, 2015 · 139 pages

Ask Your Question

Generics in Japan
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: